How much funding has Taysha Gene Therapies raised?

Taysha Gene Therapies has raised $125.0M in total funding, most recently a Series B round.

Who are Taysha Gene Therapies's investors?

Taysha Gene Therapies's investors include Fidelity Management, GV, BlackRock.

When was Taysha Gene Therapies founded?

Taysha Gene Therapies was founded in 2020.

Where is Taysha Gene Therapies headquartered?

Taysha Gene Therapies is headquartered in Dallas, Texas, United States.

What industry is Taysha Gene Therapies in?

Taysha Gene Therapies operates in Biotech, Healthcare.

How many employees does Taysha Gene Therapies have?

Taysha Gene Therapies has 51-200 employees.

Taysha Gene Therapies

IPO

Taysha GTx

Public · Dallas, United States · Founded 2020 · $125.0M raised

Biotech

Healthcare

Headquarters: Dallas, Texas
Employees: 51–200
Founded: 2020
Business Model: B2B
Website: tayshagtx.com

Total Funding: $125.0M
Last Round: $95.0M Series BAug 2020
Rounds: 2
Type: Public

About

Taysha Gene Therapies is a clinical-stage biotechnology company focused on developing AAV-based gene therapies for severe monogenic diseases of the central nervous system. Its lead program TSHA-102 targets Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies. Founded in 2020 and headquartered in Dallas, Texas, the company's management team has proven experience in gene therapy development and commercialization.

Summary

Taysha Gene Therapies is a Biotech company based in Dallas, United States, founded in 2020. It has raised $125.0M in total across 2 rounds, most recently a $95.0M Series B round in Aug 2020. Investors include Fidelity Management, GV and BlackRock.

LinkedIn X (Twitter)